About Us

About CytoTrack

CytoTrack ApS was established in 2004, and the first product was released on the market in 2011.


Tom Hede Markussen, PhD CEO (Chief Executive Officer) and Founder


Lars Marcus Pedersen (Chairman, Attorney)
Christian Caspersen (Founder)
Lars Ulrik Nielsen (Founder, CEO of 2C A/S)


CytoTrack technology is patented.


The technology was invented as a part of a research development project at The National Hospital of Denmark. The project was headed by Professor John Philip.The application was to identify FCMB (Foetal Cells in Maternal Blood).

The project discovered that conventional instruments such as flowcytometry and common fluorescent scanners were not good enough for this type of application and could not detect the extremely rare foetal cells and could not offer features for molecular characterization.

The CytoTrack technology was invented and developed specifically for the challenges of rare cell detection by Christian Caspersen. Other applications such as detection of CTCs were soon adopted.

In 2004, the first recognized paper about CTCs were published in The New England Journal of Medicine. This paper was the first to demonstrate the clinical value of enumeration of CTCs. Since then, CytoTrack has developed and optimized CytoTrack technology to show breakthrough performance within the CTC application.

In 2011, CytoTrack commercially released the CytoTrack technology.

In 2015, CytoTrack launched the CT11™ system incorporating cell picking from the disc (CytoPicker™).

In 2018 CytoTrack received funding for the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 823312, for the CytoPro clinical trial.